Skip to main content

Main menu

  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • FAQ
    • Annual Report
  • Why new TB Drugs?
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
    • Louder Than TB
  • R&D
    • Scientific Vision
    • Our Pipeline
    • Developing New Regimens
    • Discovery
    • Innovations
  • Access
    • Our Commitment
    • Understanding the TB Market
    • Engaging Communities
    • Introducing Products
  • Child Survival
    • Child-friendly medicines
    • Child TB Resources
  • News
    • Latest News
    • Publications
    • Voices of TB
    • Research Papers
  • Donate

Search form

Publications

Global Investments in Tuberculosis Research and Development

  • Click here to download the full report

New Pathways for Childhood TB Treatment

  • Click here to download the full report

2016 Annual Report

  • Click here to view the online report

Other Publications

Falling Short: Ensuring Access to Simple, Safe and Effective First-Line Medicines for Tuberculosis

  • Click here to download the report

New TB Regimens: What Countries Want

  • Click here to download the report

Pathway to Patients

Pathway to Patients is the first comprehensive analysis of how today's TB drugs reach patients on a global scale.

  • > Study Overview
  • > Compendium of Findings
  • > Country-specific results

The Economics of TB Drug Development

  • > Executive Summary
  • > Full report

Scientific Blueprint for TB Drug Development

  • > Executive Summary
  • > Full Blueprint

Annual Reports & Statements

2016 TB Alliance Financial Statement

2016 Annual Report

Making An Impact

2015 TB Alliance Financial Statement

2015 Annual Report

Reaching Further

2014 TB Alliance Financial Statement

2014 TB Alliance Annual Report

What it takes

2013 TB Alliance Financial Statement

2013 TB Alliance Annual Report

Change starts here

2012 TB Alliance Financial Statement

2012 TB Alliance Annual Report

Realizing the Promise

2011 TB Alliance Financial Statement

2011 TB Alliance Annual Report

Crossing Thresholds

2010 TB Alliance Financial Statement

2010 TB Alliance Annual Report

More Than Ever

TB Alliance 2009 Financial Statement

2009 TB Alliance Annual Report

Accelerating the Pace

TB Alliance 2008 Financial Statement

TB Alliance 2008 Annual Report

Combating TB: What it Takes

TB Alliance 2007 Annual Report

Advancing the Pathway: Novel approaches to getting faster and better TB drugs to patients

TB Alliance 2005/2006 Annual Report

TB Alliance 2004/2005 Annual Report

TB Alliance 2003/2004 Annual Report

TB Alliance 2002/2003 Annual Report

TB Alliance 2001/2002 Annual Report

Join our mailing list and receive the latest news from TB Alliance.
Interests

Our Mission

TB Alliance is a not-for-profit organization dedicated to the discovery and development of better, faster-acting, and affordable tuberculosis drugs that are available to those who need them.

Navigate

  • About
  • Why new TB Drugs?
  • R&D
  • Access
  • Child Survival
  • News
  • Donate

News Headlines

After World TB Day, High Expectations for Action
Nancy Miller-Rich Joins TB Alliance Board of Directors
ZeNix Clinical Trial Announced

Contact Us

Press Inquiries

C.J. Volpe
p | +1 646 616 8613
e | cj.volpe@tballiance.org

Thomas Lynch
p | +1 646 616 8639
e | thomas.lynch@tballiance.org

Jobs

View job openings at the TB Alliance

New York:

40 Wall Street, 24th floor, New York, NY 10005 • +1 212 227 7540

Pretoria:

Boardwalk Office Park, Block 1/Suite 5, 107 Haymeadow Street, Faerie Glen, Pretoria 0043, South Africa • +27 87 700 3900
© 2018 The TB Alliance. All Rights Reserved. Site by Darby Communications